Furmonertinib Generates Activity and Tolerable Safety in EGFR Exon 20 Insertion+ NSCLC
September 10th 2023
The use of the oral, brain penetrant, furmonertinib, resulted in encouraging responses and a tolerable safety profile in patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations, according to data from the phase 1b FAVOUR trial.